The Benefits of Quitting Smoking for Mental Health

Oct.10.2023
The Benefits of Quitting Smoking for Mental Health
Quitting smoking benefits mental health and reduces the risk of psychological disorders, according to a study published in JAMA.

According to a report by Matabandung on October 8, while some people believe that smoking can alleviate stress and soothe the soul, in reality, they may unknowingly be suffering from mental illness.


A study published in the Journal of the American Medical Association (JAMA) by the Nuffield Department of Primary Health Sciences reveals that quitting smoking is associated with significantly greater benefits compared to continuing smoking.


The project's researcher, Gao Min, stated, "We have employed three statistical methods to avoid result confusion, and therefore can provide strong evidence to suggest that quitting smoking is actually beneficial to both physical and mental health, rather than harmful." His research found that individuals who quit smoking are at a lower risk of developing mental illnesses and need not worry excessively about changes in their emotions.


Non-smokers are actually more productive than smokers. They find it easier to achieve their goals in social settings and are more effective at completing daily tasks. Additionally, they do not experience the guilt often associated with smoking due to stress.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

New Zealand Survey Finds Adult Daily Vaping Prevalence at 11.7%, Concentrated Among Youth and Disadvantaged Groups)
New Zealand Survey Finds Adult Daily Vaping Prevalence at 11.7%, Concentrated Among Youth and Disadvantaged Groups)
A survey report released by the Public Health Communication Centre Aotearoa shows that despite New Zealand implementing stricter vaping regulations in 2025, including a ban on disposable products and tighter flavour restrictions, daily vaping rates continue to rise. The research body urges close monitoring of behavioural changes following the new rules coming into force.
Dec.05 by 2FIRSTS.ai
ZYN Rolls Out “X-Low” Campaign in the UK to Target Low-Strength Nicotine Pouch Market
ZYN Rolls Out “X-Low” Campaign in the UK to Target Low-Strength Nicotine Pouch Market
Philip Morris International’s (PMI) nicotine pouch brand ZYN has launched an “X-Low” low-strength campaign in the UK, accelerating its push into the ultra-low nicotine pouch segment, with updated packaging and new flavours already rolled out in both the UK and the Philippines.
Dec.09 by 2FIRSTS.ai
PMI’s Smoke-Free Playbook: What Jacek Olczak Really Told Wall Street
PMI’s Smoke-Free Playbook: What Jacek Olczak Really Told Wall Street
At the Morgan Stanley Global Consumer & Retail Conference on December 2, 2025, PMI CEO Jacek Olczak delivered a clear message: the company’s smoke-free shift is now its central strategy. From ZYN’s surge in the U.S. to IQOS’s global momentum and a changing regulatory tone, his remarks sounded less like an earnings update and more like a declaration of PMI’s smoke-free future.
PMI
Dec.03
Product | VOZOL Mega 50K Launches in UK Channels: 18ml, 50,000-Puff Claim, Compliance Info Not Yet Public
Product | VOZOL Mega 50K Launches in UK Channels: 18ml, 50,000-Puff Claim, Compliance Info Not Yet Public
VOZOL's Vozol Mega 50K disposable e-cigarette debuts in UK, featuring 18ml e-liquid and 50,000 puff claim. Two versions available.
Dec.24 by 2FIRSTS.ai
French Council of State Strikes Down Total Vape Ban in French Polynesia
French Council of State Strikes Down Total Vape Ban in French Polynesia
France’s highest administrative court, the Council of State, has ruled that Article 76 of French Polynesia’s tobacco law establishing a total ban on vaping products is illegal. The provision, adopted in August and due to take effect by 2027, was successfully challenged by local importers and distributors.
Dec.25 by 2FIRSTS.ai
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.
Dec.02 by 2FIRSTS.ai